Natera, INC Form 4 insider transactions

Natera's President and Chief Business Officer, John Fesko, acquired a total of 54,316 shares of common stock on January 16, 2025, through the vesting of performance-based Restricted Stock Units (RSUs).

Natera CEO Steven Chapman exercised stock options and received performance-based restricted stock units, resulting in a change in his beneficial ownership of company stock.

Natera's Chief Financial Officer, Michael Brophy, acquired 39,730 shares of common stock and 24,348 shares through the vesting of restricted stock units on January 16, 2025.

Daniel Rabinowitz, SEC. AND CHIEF LEGAL OFFICER of Natera, Inc., sold 6,223 shares of common stock at an average price of $175.3015 per share.

Natera co-founder Jonathan Sheena sold a total of 6,260 shares of common stock on January 2, 2025, through pre-arranged 10b5-1 trading plans.

Natera's President and Chief Business Officer, John Fesko, acquired 1,675 shares of common stock through vested Restricted Stock Units (RSUs) and subsequently sold shares to cover tax obligations.

Natera's President of Clinical Diagnostics, Solomon Moshkevich, sold a portion of his shares to cover tax obligations after the vesting of restricted stock units.

Natera's President of Clinical Diagnostics, Solomon Moshkevich, reported donating shares of company stock to charity in two separate transactions.

Natera co-founder Jonathan Sheena sold a total of 7,200 shares of common stock on December 18, 2024, through pre-arranged 10b5-1 trading plans.

Natera's Executive Chairman, Matthew Rabinowitz, sold a significant number of shares on December 13, 2024, under a pre-arranged Rule 10b5-1 trading plan.

A Natera Inc. executive sold 1,767 shares of common stock at a weighted average price of $170.2367 per share.

A Natera executive exercised stock options and sold shares to cover tax obligations, with sales prices ranging from $166.5937 to $166.5938 per share.

Natera's Executive Chairman, Matthew Rabinowitz, exercised stock options and reported changes in his beneficial ownership of the company's stock.

Director Roelof Botha sold a total of 87,473 shares of Natera, Inc. common stock through estate planning vehicles on December 2, 2024.

Natera's Executive Chairman, Matthew Rabinowitz, sold a portion of his shares through a pre-arranged 10b5-1 trading plan.

A Natera director, Gail Boxer Marcus, sold a total of 9,682 common stock shares in multiple transactions on November 19, 2024.

Director Roy D. Baynes of Natera, Inc. exercised stock options and sold shares on November 15, 2024, under a pre-arranged 10b5-1 trading plan.

Natera CEO Steven Chapman sold a total of 4,728 shares of common stock on November 15, 2024, under a pre-arranged 10b5-1 trading plan.

Natera co-founder Jonathan Sheena sold a significant number of shares on November 13, 2024, under pre-arranged 10b5-1 trading plans.

A Natera director, Gail Boxer Marcus, sold a total of 2,212 shares of common stock in multiple transactions on November 14, 2024.

Natera's Executive Chairman, Matthew Rabinowitz, exercised stock options, increasing his direct holdings of common stock.

Natera co-founder Jonathan Sheena sold a total of 7,300 shares of common stock on November 8, 2024, through a pre-arranged 10b5-1 trading plan.

Michael Brophy, CFO of Natera, Inc., sold 1,866 shares of common stock at a price of $126.45 per share on October 31, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Daniel Rabinowitz, SEC. and Chief Legal Officer of Natera, Inc., reported the sale of 1,057 shares of common stock to cover tax obligations related to vesting RSUs.

Solomon Moshkevich, President of Clinical Diagnostics at Natera, Inc., sold 1,196 shares of common stock to cover tax obligations related to vesting RSUs.

John Fesko, President and Chief Business Officer of Natera, Inc., sold 929 shares of common stock to cover tax obligations related to vesting RSUs.

Natera CEO Steven Chapman sold 3,960 shares of common stock on October 28, 2024, to satisfy tax withholding obligations related to vesting RSUs.

Michael Brophy, CFO of Natera, Inc., sold shares of common stock to cover tax obligations related to vesting RSUs and under a pre-arranged 10b5-1 trading plan.

Director Herm Rosenman acquired 178 shares of Natera, Inc. common stock through the issuance of fully vested Restricted Stock Units (RSUs) in lieu of quarterly retainer fees.

Director James Healy received 153 fully vested Restricted Stock Units (RSUs) from Natera in lieu of quarterly retainer fees.